179 related articles for article (PubMed ID: 19180138)
21. Current insight into thrombotic thrombocytopenic purpura.
Verbeke L; Delforge M; Dierickx D
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
[TBL] [Abstract][Full Text] [Related]
22. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
[TBL] [Abstract][Full Text] [Related]
23. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
[TBL] [Abstract][Full Text] [Related]
24. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.
Goyal J; Adamski J; Lima JL; Marques MB
J Clin Apher; 2013 Dec; 28(6):390-4. PubMed ID: 23857472
[TBL] [Abstract][Full Text] [Related]
25. Thrombotic thrombocytopenic purpura-what is new?
Shah N; Sarode R
J Clin Apher; 2013 Feb; 28(1):30-5. PubMed ID: 23420593
[TBL] [Abstract][Full Text] [Related]
26. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.
Dane K; Chaturvedi S
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):539-547. PubMed ID: 30504355
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application.
Scully M
Blood Rev; 2010 Jan; 24(1):11-6. PubMed ID: 19963308
[TBL] [Abstract][Full Text] [Related]
28. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
Elliott MA; Heit JA; Pruthi RK; Gastineau DA; Winters JL; Hook CC
Eur J Haematol; 2009 Oct; 83(4):365-72. PubMed ID: 19508684
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for TTP.
Scott SM; Szczepiorkowski ZM
Am J Hematol; 2005 Sep; 80(1):87-8. PubMed ID: 16138332
[No Abstract] [Full Text] [Related]
30. Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.
Froissart A; Veyradier A; Hié M; Benhamou Y; Coppo P;
Eur J Intern Med; 2015 Nov; 26(9):659-65. PubMed ID: 26293834
[TBL] [Abstract][Full Text] [Related]
31. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib.
van Balen T; Schreuder MF; de Jong H; van de Kar NC
Eur J Haematol; 2014 Jan; 92(1):80-2. PubMed ID: 24118335
[TBL] [Abstract][Full Text] [Related]
32. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.
Ling HT; Field JJ; Blinder MA
Am J Hematol; 2009 Jul; 84(7):418-21. PubMed ID: 19507208
[TBL] [Abstract][Full Text] [Related]
33. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
Becerra E; Scully MA; Leandro MJ; Heelas EO; Westwood JP; De La Torre I; Cambridge G
Clin Exp Immunol; 2015 Mar; 179(3):414-25. PubMed ID: 25339550
[TBL] [Abstract][Full Text] [Related]
34. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide.
Fakhouri F; Teixeira L; Delarue R; Grünfeld JP; Veyradier A
Ann Intern Med; 2004 Feb; 140(4):314-5. PubMed ID: 14970167
[No Abstract] [Full Text] [Related]
35. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
[TBL] [Abstract][Full Text] [Related]
36. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
Shortt J; Oh DH; Opat SS
N Engl J Med; 2013 Jan; 368(1):90-2. PubMed ID: 23281998
[No Abstract] [Full Text] [Related]
37. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
38. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP.
Darabi K; Berg AH
Am J Clin Pathol; 2006 Apr; 125(4):592-7. PubMed ID: 16627268
[TBL] [Abstract][Full Text] [Related]
39. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab.
Caramazza D; Quintini G; Abbene I; Malato A; Saccullo G; Lo Coco L; Di Trapani R; Palazzolo R; Barone R; Mazzola G; Rizzo S; Ragonese P; Aridon P; Abbadessa V; Siragusa S
Transfusion; 2010 Dec; 50(12):2753-60. PubMed ID: 20576013
[TBL] [Abstract][Full Text] [Related]
40. [Recent therapeutic strategy for thrombotic thrombocytopenic purpura].
Fujimura Y; Matsumoto M; Isonishi A; Yagi H; Kokame K; Miyata T
Rinsho Ketsueki; 2014 Jan; 55(1):93-104. PubMed ID: 24492042
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
